NCT06391450View on ClinicalTrials.gov

Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

PHASE4RecruitingINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Autosomal Dominant Polycystic Kidney

Interventions

DRUG

Empagliflozin 10 MG

Oral

DRUG

Placebo

Oral

Trial Locations (1)

30625

RECRUITING

Medizinische Hochschule Hannover, Hanover

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Hannover Medical School

OTHER